Dosing Begins in Phase 1 Trial of CERC-007
Cerecor has dosed the first patient in a Phase 1b clinical trial evaluating  CERC-007 as a potential treatment for relapsed or refractory multiple…
News
Jakafi Plus Steroid Continuing to Treat Multiple Myeloma in Phase 1 Trial
Combining the corticosteroid methylprednisolone and Jakafi (ruxolitinib), an approved oral therapy for bone marrow disorders, is showing promising effectiveness in heavily pre-treated multiple myeloma…
$10M Gift to Open Myeloma Research Center at Ohio State
A new research center at Ohio State University (OSU) aims to speed work into the discovery and development of more effective treatments for those with…
First Patient Dosed With CYAD-211, a Potential CAR T-cell Therapy
The first patient has been dosed in Celyad Oncology’s Phase 1 clinical trial evaluating CYAD-211, an investigational donor-derived CAR T-cell therapy for treating relapsed…
Early Data Show TNB-383B to be Safe, Effective for Heavily Treated Myeloma
Teneobio‘s bispecific antibody TNB-383B was found to be well-tolerated and induced a high response rate among people with heavily treated multiple myeloma in an…
FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma.
First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo
The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex…
PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy and safety data in an early clinical trial of heavily-pretreated people with relapsed or refractory…
MMRF Invests in Indapta’s Natural Killer Cell Therapy to Advance Clinical Trials
The Multiple Myeloma Research Foundation (MMRF) is partnering with Indapta Therapeutics to advance the biotechnology company’s investigational G-NK cell therapy into clinical trials…
FDA Approval Sought for Cilta-cel CAR T-cell Therapy
Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel — known as cilta-cel — to treat adults…
Recent Posts
- Low muscle mass linked to worse outcomes with chemoradiotherapy
- Dordaviprone under FDA priority review for aggressive glioma type
- FDA decision on linvoseltamab in treating RRMM expected in July
- CUSP06 put on FDA fast track for platinum-resistant ovarian cancer
- Tuspetinib as part of triple-combo therapy showing potential in AML